5-FU + LV

From OncoWiki
Revision as of 09:00, 17 August 2007 by Palmdoc (talk | contribs) (→‎Hepatocellular Carcinoma)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigationJump to search

Regimen

Hepatocellular Carcinoma

  • 5-FU 370 mg/m2/d iv d1-5
  • Leucovorin 200 mg/m2/d iv d1-5
  • Q4w

References

Porta, C et al. 5-Fluorouracil and d,l-leucovorin calcium are active to treat unresectable hepatocellular carcinoma patients: preliminary results of a phase II study. Oncology 1995; 52:487

Indication

Colon Cancer

Roswell park regimen

Adjuvant chemotherapy

  • 5-FU 500 mg/m2 iv bolus
  • Leucovorin 500 mg/m2 iv over 2 hrs
  • Qw x 6 wks every 8 wks for 4 cycles
References

Haller, DG et al. Phase III study of fluorouracil, leucovorin and levamisole in high-risk stage II and III colon cancer: final report of intergroup 0089. J Clin Oncol 2005; 23:8671

Mayo clinic regimen

Adjuvant chemotherapy

  • 5-FU 425 mg/m2/d iv bolus d1-5
  • Leucovorin 20 mg/m2/d iv bolus d1-5
  • Q4w x 6 cycles
References

Haller, DG et al. Phase III study of fluorouracil, leucovorin and levamisole in high-risk stage II and III colon cancer: final report of intergroup 0089. J Clin Oncol 2005; 23:8671

O'Connell, MJ et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997; 15:246

Ovarian Epithelial Cancer

Chemotherapy for recurrent or metastatic cancer

  • Leucovorin 200 mg/m2/d iv bolus followed by 5-FU 370 mg/m2/d iv bolus d1-5
  • Q4w

References

Look, KY et al. A phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent epithelial ovarian carcinoma. A Gynecologic Oncology Group Study. Am J Clin Oncol 1995; 18:19

Pancreatic Cancer

Adjuvant chemotherapy

  • 5-FU 425 mg/m2/d iv bolus d1-5
  • Leucovorin 20 mg/m2/d iv bolus d1-5
  • Q4w x 6 cycles

References

Neoptolemos, JP et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350:1200